Ken Griffin Sutro Biopharma, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.33 $22,192 - $40,508	-7,600 Reduced 97.44%	200 $0
Q1 2024 May 15, 2024	BUY	$3.27 - $5.65 $19,947 - $34,465	6,100 Added 358.82%	7,800 $44,000
Q4 2023 Feb 14, 2024	BUY	$2.07 - $4.54 $1,449 - $3,178	700 Added 70.0%	1,700 $7,000
Q3 2023 Nov 14, 2023	SELL	$3.29 - $4.9 $6,909 - $10,290	-2,100 Reduced 67.74%	1,000 $3,000
Q2 2023 Aug 14, 2023	BUY	$4.25 - $5.88 $11,050 - $15,288	2,600 Added 520.0%	3,100 $14,000
Q1 2023 May 15, 2023	SELL	$4.48 - $8.45 $15,680 - $29,574	-3,500 Reduced 87.5%	500 $2,000
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $21,640 - $32,320	4,000 New	4,000 $32,000

124

63M

200

27.6K

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $235M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.